Loading company
Decoy Therapeutics Inc.
DCOY · Nasdaq · ·
$2.11-9.4%Sep 29 close
- 1M
- -27.2%
- 6M
- -68.8%
- 1Y
- -95.2%
- 5Y
- -100.0%
What Decoy Therapeutics Inc. reported on July 31, 2025
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toSep 30, 2022 | Change |
|---|---|---|---|
| Total Revenue | $227.6K | $0.00 | — |
| Profit | -$2.4M | -$957.8K | -147.83% |
| Profit per share | $7.42 | -$0.35 | +2,235.25% |
| Free Cash Flow | $387.5K | -$5.8M | +106.72% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
Decoy Therapeutics Inc. has no earnings call transcript available.
How the share price reacted
Releases land after the close or before the open, so the move is the session that follows.
Close before
$107.87
Jul 31, 2025
Close after
$113.40
Aug 1, 2025
Move
+5.13%
0 shares traded, against a normal 0
The quote and the company description come from Decoy Therapeutics Inc.’s Item 2.02 8-K filed July 31, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.